250 results on '"Afif, W."'
Search Results
2. A259 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH MULTI-ORGAN COMORBIDITIES AND FIBROSIS PROGRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
3. A278 ACCEPTABILITY, FEASIBILITY, AND IMPACT OF THE MYGUT DIGITAL HEALTH PLATFORM IN THE MONITORING AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE
4. A252 DRUG DISCONTINUATION AND PERSISTENT SYMPTOMS AMONG THE USERS OF BIOSIMILAR AND LEGACY ANTI-TNF DRUGS IN A REAL-WORLD CANADIAN IBD COHORT
5. P306 Rectal bleeding and stool frequency are strong predictors of endoscopic and histologic activity in ulcerative colitis patients, a prospective cohort study
6. P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study
7. P412 Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis
8. P716 Efficacy and safety of upadacitinib during induction in Crohn’s disease: Real-world experience
9. P672 Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysis
10. A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
11. P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
12. P417 Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
13. Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
14. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience
15. The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)
16. P763 Fucosyltransferase 2 non-secretor status in Crohnʼs disease: a prospective observational analysis
17. P677 Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel disease
18. P626 Ustekinumab for the treatment of perianal fistulas in patients with Crohnʼs disease
19. P342 Maladaptive coping, self-efficacy and patient reported outcomes in inflammatory bowel disease
20. P157 Fecal calprotectin correlates to endoscopic and histologic remission in ulcerative colitis: a prospective study
21. A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
22. A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
23. A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
24. P321 Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm study
25. P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis
26. P524 Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn’s disease
27. P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts
28. DOP25 Clinical outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
29. P582 Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
30. P451 Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study
31. POS1420 RISK OF SERIOUS INFECTIONS IN OFFSPRING EXPOSED IN UTERO TO USTEKINUMAB OR VEDOLIZUMAB
32. P643 Patient perspectives and expectations in inflammatory bowel disease: a systematic review
33. P119 There is minimal agreement on the recognition of deep ulcers as seen on endoscopy in patients with Inflammatory Bowel Disease: a national survey
34. P364 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study
35. DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension
36. DOP26 The relationship between vedolizumab therapeutic drug monitoring, biomarkers of inflammation, and clinical outcomes in Inflammatory Bowel Disease in the real-world setting
37. DOP18 UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: Final results from a prospective study
38. P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
39. DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
40. P552 Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort
41. A192 A MEDICAL SUMMARY TEMPLATE FOR THE TRANSFER OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TRANSITIONING FROM PEDIATRIC TO ADULT CARE
42. A174 PATIENT PERSPECTIVES AND EXPECTATIONS IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW
43. A157 REAL-WORLD TIGHT OBJECTIVE MONITORING WITH ADALIMUMAB LEADS TO EARLIER DOSE OPTIMIZATION AND HIGHER CLINICAL REMISSION RATES AT 12 MONTHS.
44. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
45. Review article: a clinicianʼs guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
46. A232 EFFICACY OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS: REAL-WORLD DATA
47. P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
48. DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
49. Undiagnosed depression, persistent depressive symptoms and seeking mental health care: analysis of immigrant and non-immigrant participants of the Canadian Longitudinal Study of Aging
50. P841 Evaluation of gut microbiota composition in NAFLD with UC pancolitis in clinical remission: a pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.